Embolization of the hepatic falciform artery to prevent supraumbilical skin rash during transcatheter arterial chemoembolization for hepatocellular carcinoma

1995 ◽  
Vol 18 (3) ◽  
Author(s):  
Kazuto Ueno ◽  
Nobuaki Miyazono ◽  
Hiroki Inoue ◽  
Satoshi Miyake ◽  
Hirotoshi Nishida ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skin Rash ◽  
Transcatheter Arterial Chemoembolization ◽  
Hepatic Falciform Artery ◽  
Arterial Chemoembolization

scholarly journals Supraumbilical skin rash after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: Two case report

Kanzo ◽  
2009 ◽  
Vol 50 (7) ◽  
pp. 390-396
Author(s):  
Mio Kawakami ◽  
Mikiya Kitamoto ◽  
Ikue Noda ◽  
Ryohei Hayashi ◽  
Mio Tanaka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Skin Rash ◽  
Transcatheter Arterial Chemoembolization ◽  
Arterial Chemoembolization

Radial Artery Approach for Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma

2002 ◽  
Vol 46 (3) ◽  
pp. 229
Author(s):  
Seung Hun Ryu ◽  
Hyung Jin Shim ◽  
Byung Kook Kwak ◽  
Gi Hyun Kim ◽  
Hwa Yeon Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radial Artery ◽  
Transcatheter Arterial Chemoembolization ◽  
Arterial Chemoembolization

scholarly journals Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chuang Jiang ◽  
Gong Cheng ◽  
Mingheng Liao ◽  
Jiwei Huang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Transcatheter Arterial Chemoembolization ◽  
Meta Analysis ◽  
Combined Treatment ◽  
Similar Rate ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Knowledge Infrastructure ◽  
Arterial Chemoembolization

Abstract Background There is still some debate as to whether transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) is better than TACE or RFA alone. This meta-analysis aimed to compare the efficacy and safety of TACE plus RFA for hepatocellular carcinoma (HCC) with RFA or TACE alone. Methods We searched PubMed, MEDLINE, Embase, Cochrane Library, and CNKI (China National Knowledge Infrastructure) for all relevant randomized controlled trials and retrospective studies reporting overall survival (OS), recurrence-free survival (RFS), and complications of TACE plus RFA for HCC, compared with RFA or TACE alone. Results Twenty-one studies involving 3413 patients were included. TACE combined with RFA was associated with better OS (hazard ratio [HR]=0.62, 95% confidence intervals [CI] = 0.55–0.71, P < 0.001) and RFS (HR = 0.52, 95% CI = 0.39–0.69, P < 0.001) than TACE alone; compared with RFA alone, TACE plus RFA resulted in longer OS (HR = 0.63, 95% CI = 0.53–0.75, P < 0.001) and RFS (HR = 0.60, 95% CI = 0.51–0.71, P < 0.001). Subgroup analyses by tumor size also showed that combined treatment resulted in better OS and RFS compared with RFA alone in patients with HCC larger than 3 cm. Combined treatment resulted in similar rate of major complications compared with TACE or RFA alone (OR = 1.78, 95% CI = 0.99–3.20, P = 0.05; OR = 1.00, 95% CI = 0.42–2.38, P = 1.00, respectively). Conclusions TACE combined with RFA was more effective for HCC than TACE alone. For patients with a tumor larger than 3 cm, the combined treatment also achieved a better effect than RFA alone.

Sign in / Sign up

Export Citation Format

Share Document